AKEBIA THERAPEUTICS, INC. Additional Paid in Capital, Common Stock
AKEBIA THERAPEUTICS, INC. (AKBA) had Additional Paid in Capital, Common Stock of $1.73 billion as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:AdditionalPaidInCapitalCommonStock · last filed 2026-08-05
- 2026-06-30: Additional Paid in Capital, Common Stock $1.73B.
- 2026-03-31: Additional Paid in Capital, Common Stock $1.72B.
- 2025-12-31: Additional Paid in Capital, Common Stock $1.72B.
- 2025-09-30: Additional Paid in Capital, Common Stock $1.71B.
| Period end | Additional Paid in Capital, Common Stock |
|---|---|
| 2026-06-30 | $1.73B 10-Q · filed 2026-08-05 |
| 2026-03-31 | $1.72B 10-Q · filed 2026-05-07 |
| 2025-12-31 | $1.72B 10-Q · filed 2026-08-05 |
| 2025-09-30 | $1.71B 10-Q · filed 2025-11-10 |
| 2025-06-30 | $1.70B 10-Q · filed 2025-08-07 |
| 2025-03-31 | $1.70B 10-Q · filed 2025-05-08 |
| 2024-12-31 | $1.63B 10-K · filed 2026-02-26 |
| 2024-09-30 | $1.61B 10-Q · filed 2024-11-07 |
| 2024-06-30 | $1.60B 10-Q · filed 2024-08-08 |
| 2024-03-31 | $1.60B 10-Q · filed 2024-05-09 |
| 2023-12-31 | $1.58B 10-K · filed 2025-03-13 |
| 2023-09-30 | $1.57B 10-Q · filed 2023-11-08 |
| 2023-06-30 | $1.57B 10-Q · filed 2023-08-28 |
| 2023-03-31 | $1.56B 10-Q · filed 2023-05-08 |
| 2022-12-31 | $1.56B 10-K · filed 2024-03-14 |
| 2022-09-30 | $1.56B 10-Q · filed 2022-11-03 |
| 2022-06-30 | $1.56B 10-Q · filed 2022-08-04 |
| 2022-03-31 | $1.55B 10-Q · filed 2022-05-09 |
| 2021-12-31 | $1.54B 10-K/A · filed 2023-08-28 |
| 2021-09-30 | $1.53B 10-Q · filed 2021-11-04 |
| 2021-06-30 | $1.50B 10-Q · filed 2021-08-05 |
| 2021-03-31 | $1.46B 10-Q · filed 2021-05-10 |
| 2020-12-31 | $1.43B 10-K · filed 2022-03-01 |
| 2020-09-30 | $1.41B 10-Q · filed 2020-11-05 |
| 2020-06-30 | $1.40B 10-Q · filed 2020-08-10 |
| 2020-03-31 | $1.25B 10-Q · filed 2020-05-05 |
| 2019-12-31 | $1.19B 10-K · filed 2021-02-25 |
| 2019-09-30 | $1.17B 10-Q · filed 2019-11-12 |
| 2019-06-30 | $1.16B 10-Q · filed 2019-08-08 |
| 2019-03-31 | $1.15B 10-Q · filed 2019-05-09 |
| 2018-12-31 | $1.15B 10-K · filed 2020-03-12 |
| 2018-09-30 | $597.29M 10-Q · filed 2018-11-08 |
| 2018-06-30 | $594.68M 10-Q · filed 2018-08-08 |
| 2018-03-31 | $591.87M 10-Q · filed 2018-05-09 |
| 2017-12-31 | $493.82M 10-K · filed 2019-03-26 |
| 2017-09-30 | $486.39M 10-Q · filed 2017-11-08 |
| 2017-06-30 | $420.45M 10-Q · filed 2017-08-08 |
| 2017-03-31 | $372.48M 10-Q · filed 2017-05-09 |
| 2016-12-31 | $365.30M 10-K · filed 2018-03-12 |
| 2016-09-30 | $359.99M 10-Q · filed 2016-11-09 |
| 2016-06-30 | $356.22M 10-Q · filed 2016-08-08 |
| 2016-03-31 | $355.14M 10-Q · filed 2016-05-05 |
| 2015-12-31 | $292.78M 10-K · filed 2017-03-06 |
| 2015-09-30 | $287.11M 10-Q · filed 2015-11-09 |
| 2015-06-30 | $272.00M 10-Q · filed 2015-08-11 |
| 2015-03-31 | $206.15M 10-Q · filed 2015-05-11 |
| 2014-12-31 | $204.97M 10-K · filed 2016-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |